THE WIRE · № 81474
SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Study
01 THE MACHINE READ
WHY IT MATTERS.
NIH validation of a diagnostic endpoint could support SciBase's clinical credibility, but the company is a small Nordic listing.
Small-cap device validation, no broad sector read
Study enrollment or peer-reviewed results
Study may not confirm the technology
FULL DISPATCH
STOCKHOLM, Oct. 15, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that a new study will be initiated in a collaboration between NIH (National Institute of Health, US) and the Swiss...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
IAM IPO News - Small molecule biotech Iambic Therapeutics prices IPO at $16, the midpoint of the range2026-10-15 06:07 UTC
Rush, Endeavor healthcare companies announce merger plans2026-10-14 15:11 UTC
Merck CEO says he expects breakthrough cancer vaccine will become faster to make2026-10-14 20:00 UTC
American politicians are uniting against animal testing2026-10-14 23:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.